YieldMax AMD Option Income Strategy ETF vs Illumina, Inc. — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $54, while Illumina, Inc. trades at $190.6 (market cap $28.78B). The key difference: Illumina, Inc. is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | ILMN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $194.33 |
52-Week Low | $29.80 | $91.00 |
Market Cap | — | $28.78B |
Enterprise Value | — | $30.17B |
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
Illumina (ILMN) trades at $190.20, down 1.84% on the day but up significantly year-to-date with strong momentum. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reflect a turnaround with net income reaching $850 million in 2025 after previous losses. Recent news highlights product launches and leadership appointments, with the company scheduled to report Q2 2026 earnings on July 30, 2026.
The outlook remains positive with analyst consensus leaning bullish, though valuation multiples appear elevated. Key risks include competitive pressure from new entrants like Roche's Axelios sequencer and execution challenges in maintaining profitability growth. The upcoming earnings report will be critical for validating the current rally's sustainability.
Trailing returns across standard periods
Latest headlines on both assets
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →